Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

• Tom Martin,
• Paul G Richardson,
• Thierry Facon,
• Philippe Moreau,
• Aurore Perrot,
• Ivan Spicka,
• Kamlesh Bisht,
• Marlene Inchauspé,
• France Casca,
• Sandrine Macé,
• Helgi van de Velde,
• Kenshi Suzuki

Affiliations

Tom Martin

UCSF Medical Center, San Francisco, CA

Paul G Richardson

Dana-Farber Cancer Institute, Boston, MA

Thierry Facon

Department of Haematology, Lille University Hospital, Lille

Philippe Moreau

Department of Hematology, University Hospital of Nantes, Nantes

Aurore Perrot

Centre Hospitalo-Universitaire (CHU) de Toulouse, Centre de Recherches en Cancérologie de Toulouse (CRCT), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, UPS, Toulouse

Ivan Spicka

First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic

Kamlesh Bisht

Sanofi, Research and Development, Cambridge, MA

Marlene Inchauspé

IT-M Statistics for Sanofi, Neuilly sur-Seine

France Casca

IVIdata for Sanofi, Levallois-Perret

Sandrine Macé

Sanofi, Research and Development, Vitry-Sur-Seine

Helgi van de Velde

Sanofi, Research and Development, Cambridge, MA

Kenshi Suzuki

Department of Hematology, Japanese Red Cross Medical Center, Tokyo